The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma

Deepa Bhojwani, Mary B. Mccarville, John K. Choi, Jennifer Sawyer, Monika L. Metzger, Hiroto Inaba, Andrew M. Davidoff, Robert Gold, Barry L. Shulkin, John T. Sandlund

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Summary: 18F-labelled-fluorodeoxyglucose positron emission tomography (FDG-PET) findings are challenging to interpret for residual disease versus complete response in paediatric patients with non-Hodgkin lymphoma (NHL). A biopsy is often warranted to confirm the presence or absence of viable tumour if there is clinical or radiographic evidence of residual disease. In this study, we compared conventional imaging and FDG-PET/computerized tomography (CT) findings with biopsy results in 18 children with NHL. Our goal was to provide additional data to establish more reliable criteria for response evaluation. Residual disease was suspected after conventional imaging alone in eight patients, after FDG-PET/CT alone in three and after both modalities in seven patients. Biopsy confirmed the presence of viable tumour in two patients. Two additional patients experienced progressive disease or relapse. The sensitivity and negative predictive value of FDG-PET/CT using the London criteria to indicate residual tumour detectable by biopsy were 100%, but specificity was low (60%), as was the positive predictive value (25%). Thus, in this study, a negative FDG-PET/CT finding was a good indicator of complete remission. However, because false-positive FDG-PET/CT findings are common, biopsy and close monitoring are required for accurate determination of residual disease in individual patients.

Original languageEnglish (US)
Pages (from-to)845-853
Number of pages9
JournalBritish Journal of Haematology
Volume168
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Positron-Emission Tomography
Non-Hodgkin's Lymphoma
Tomography
Pediatrics
Biopsy
Fluorodeoxyglucose F18
Residual Neoplasm
Neoplasms
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Bhojwani, D., Mccarville, M. B., Choi, J. K., Sawyer, J., Metzger, M. L., Inaba, H., ... Sandlund, J. T. (2015). The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. British Journal of Haematology, 168(6), 845-853. https://doi.org/10.1111/bjh.13219

The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. / Bhojwani, Deepa; Mccarville, Mary B.; Choi, John K.; Sawyer, Jennifer; Metzger, Monika L.; Inaba, Hiroto; Davidoff, Andrew M.; Gold, Robert; Shulkin, Barry L.; Sandlund, John T.

In: British Journal of Haematology, Vol. 168, No. 6, 01.01.2015, p. 845-853.

Research output: Contribution to journalArticle

Bhojwani, D, Mccarville, MB, Choi, JK, Sawyer, J, Metzger, ML, Inaba, H, Davidoff, AM, Gold, R, Shulkin, BL & Sandlund, JT 2015, 'The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma', British Journal of Haematology, vol. 168, no. 6, pp. 845-853. https://doi.org/10.1111/bjh.13219
Bhojwani, Deepa ; Mccarville, Mary B. ; Choi, John K. ; Sawyer, Jennifer ; Metzger, Monika L. ; Inaba, Hiroto ; Davidoff, Andrew M. ; Gold, Robert ; Shulkin, Barry L. ; Sandlund, John T. / The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. In: British Journal of Haematology. 2015 ; Vol. 168, No. 6. pp. 845-853.
@article{528e750a86fd4508b461427e9c0fe262,
title = "The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma",
abstract = "Summary: 18F-labelled-fluorodeoxyglucose positron emission tomography (FDG-PET) findings are challenging to interpret for residual disease versus complete response in paediatric patients with non-Hodgkin lymphoma (NHL). A biopsy is often warranted to confirm the presence or absence of viable tumour if there is clinical or radiographic evidence of residual disease. In this study, we compared conventional imaging and FDG-PET/computerized tomography (CT) findings with biopsy results in 18 children with NHL. Our goal was to provide additional data to establish more reliable criteria for response evaluation. Residual disease was suspected after conventional imaging alone in eight patients, after FDG-PET/CT alone in three and after both modalities in seven patients. Biopsy confirmed the presence of viable tumour in two patients. Two additional patients experienced progressive disease or relapse. The sensitivity and negative predictive value of FDG-PET/CT using the London criteria to indicate residual tumour detectable by biopsy were 100{\%}, but specificity was low (60{\%}), as was the positive predictive value (25{\%}). Thus, in this study, a negative FDG-PET/CT finding was a good indicator of complete remission. However, because false-positive FDG-PET/CT findings are common, biopsy and close monitoring are required for accurate determination of residual disease in individual patients.",
author = "Deepa Bhojwani and Mccarville, {Mary B.} and Choi, {John K.} and Jennifer Sawyer and Metzger, {Monika L.} and Hiroto Inaba and Davidoff, {Andrew M.} and Robert Gold and Shulkin, {Barry L.} and Sandlund, {John T.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/bjh.13219",
language = "English (US)",
volume = "168",
pages = "845--853",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma

AU - Bhojwani, Deepa

AU - Mccarville, Mary B.

AU - Choi, John K.

AU - Sawyer, Jennifer

AU - Metzger, Monika L.

AU - Inaba, Hiroto

AU - Davidoff, Andrew M.

AU - Gold, Robert

AU - Shulkin, Barry L.

AU - Sandlund, John T.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Summary: 18F-labelled-fluorodeoxyglucose positron emission tomography (FDG-PET) findings are challenging to interpret for residual disease versus complete response in paediatric patients with non-Hodgkin lymphoma (NHL). A biopsy is often warranted to confirm the presence or absence of viable tumour if there is clinical or radiographic evidence of residual disease. In this study, we compared conventional imaging and FDG-PET/computerized tomography (CT) findings with biopsy results in 18 children with NHL. Our goal was to provide additional data to establish more reliable criteria for response evaluation. Residual disease was suspected after conventional imaging alone in eight patients, after FDG-PET/CT alone in three and after both modalities in seven patients. Biopsy confirmed the presence of viable tumour in two patients. Two additional patients experienced progressive disease or relapse. The sensitivity and negative predictive value of FDG-PET/CT using the London criteria to indicate residual tumour detectable by biopsy were 100%, but specificity was low (60%), as was the positive predictive value (25%). Thus, in this study, a negative FDG-PET/CT finding was a good indicator of complete remission. However, because false-positive FDG-PET/CT findings are common, biopsy and close monitoring are required for accurate determination of residual disease in individual patients.

AB - Summary: 18F-labelled-fluorodeoxyglucose positron emission tomography (FDG-PET) findings are challenging to interpret for residual disease versus complete response in paediatric patients with non-Hodgkin lymphoma (NHL). A biopsy is often warranted to confirm the presence or absence of viable tumour if there is clinical or radiographic evidence of residual disease. In this study, we compared conventional imaging and FDG-PET/computerized tomography (CT) findings with biopsy results in 18 children with NHL. Our goal was to provide additional data to establish more reliable criteria for response evaluation. Residual disease was suspected after conventional imaging alone in eight patients, after FDG-PET/CT alone in three and after both modalities in seven patients. Biopsy confirmed the presence of viable tumour in two patients. Two additional patients experienced progressive disease or relapse. The sensitivity and negative predictive value of FDG-PET/CT using the London criteria to indicate residual tumour detectable by biopsy were 100%, but specificity was low (60%), as was the positive predictive value (25%). Thus, in this study, a negative FDG-PET/CT finding was a good indicator of complete remission. However, because false-positive FDG-PET/CT findings are common, biopsy and close monitoring are required for accurate determination of residual disease in individual patients.

UR - http://www.scopus.com/inward/record.url?scp=84924056175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924056175&partnerID=8YFLogxK

U2 - 10.1111/bjh.13219

DO - 10.1111/bjh.13219

M3 - Article

VL - 168

SP - 845

EP - 853

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -